Pittsburgh and Epworth Sleep Scale Items: Accuracy of Ratings Across Different Reporting Periods

a Department of Psychiatry and Behavioral Science , Stony Brook University.
Behavioral Sleep Medicine (Impact Factor: 2.34). 01/2012; 11(3). DOI: 10.1080/15402002.2012.654549
Source: PubMed


This study examined the ecological validity of sleep experience reports across different lengths of reporting periods. The accuracy of item responses on the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) across 3-, 7-, and 28-day reporting periods was examined in relation to electronic daily item ratings. Primary care clinic patients (N = 119) were recruited, and were not required to have sleep problems to participate. Analyses found few differences in item scores when electronic daily ratings were compared with recall ratings, regardless of the length of the reporting period. However, within-subjects analyses indicated low levels of accuracy in recall of sleep items for specific days in the last week. Thus, for the purpose of between-subject comparisons, patients generally can provide accurate recall of sleep experiences; studies requiring finer-grained analysis across time and within-subjects require daily diary methodology.

Download full-text


Available from: Joan E Broderick, Mar 24, 2014
  • Source
    • "The sum of these components, ranging from 0 to 21, is the global PSQI score, where a score greater than 7 indicates sleep dysfunction (Gellis and Lichstein, 2009). The subjective measures of the subscores and global PSQI score are valid over different reporting periods (r ¼0.87) (Broderick et al., 2012) and correlate with other sleep quality measures (r Z0.69) (Smith and Wegener, 2003). In addition, the overall test–retest reliability (r ¼ 0.88, p ¼0.000) and homogeneity (Cronbach's alpha ¼ 0.85) are high (Backhaus et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The study examined the association between marijuana use, Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms, and sleep quality in 56 men and 20 women with ADHD. Participants, ages 18-45, were assessed with the Assessment of Hyperactivity and Attention, drug use survey, and Pittsburgh Sleep Quality Index. Moderate to strong correlations were found between marijuana use and inattentive symptoms in men, and marijuana use and decreased sleep quality in women. Men and women with ADHD may use marijuana for different reasons.
    08/2013; 210(3). DOI:10.1016/j.psychres.2013.08.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To document the monthly changes in sleep/insomnia status over a 12-month period; to determine the optimal time intervals to reliably capture new incident cases and recurrent episodes of insomnia and the likelihood of its persistence over time. Participants were 100 adults (mean age = 49.9 years; 66% women) randomly selected from a larger population-based sample enrolled in a longitudinal study of the natural history of insomnia. They completed 12 monthly telephone interviews assessing insomnia, use of sleep aids, stressful life events, and physical and mental health problems in the previous month. A total of 1,125 interviews of a potential 1,200 were completed. Based on data collected at each assessment, participants were classified into one of three subgroups: good sleepers, insomnia symptoms, and insomnia syndrome. At baseline, 42 participants were classified as good sleepers, 34 met criteria for insomnia symptoms, and 24 for an insomnia syndrome. There were significant fluctuations of insomnia over time, with 66% of the participants changing sleep status at least once over the 12 monthly assessments (51.5% for good sleepers, 59.5% for insomnia syndrome, and 93.4% for insomnia symptoms). Changes of status were more frequent among individuals with insomnia symptoms at baseline (mean = 3.46, SD = 2.36) than among those initially classified as good sleepers (mean = 2.12, SD = 2.70). Among the subgroup with insomnia symptoms at baseline, 88.3% reported improved sleep (i.e., became good sleepers) at least once over the 12 monthly assessments compared to 27.7% whose sleep worsened (i.e., met criteria for an insomnia syndrome) during the same period. Among individuals classified as good sleepers at baseline, risks of developing insomnia symptoms and syndrome over the subsequent months were, respectively, 48.6% and 14.5%. Monthly assessment over an interval of 6 months was found most reliable to estimate incidence rates, while an interval of 3 months proved the most reliable for defining chronic insomnia. Monthly assessment of insomnia and sleep patterns revealed significant variability over the course of a 12-month period. These findings highlight the importance for future epidemiological studies of conducting repeated assessment at shorter than the typical yearly interval in order to reliably capture the natural course of insomnia over time. Morin CM; LeBlanc M; Ivers H; Bélanger L; Mérette C; Savard J; Jarrin DC. Monthly fluctuations of insomnia symptoms in a population-based sample. SLEEP 2014;37(2):319-326.
    Sleep 02/2014; 37(2):319-26. DOI:10.5665/sleep.3406 · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The identification of the gene mutation causing Huntington disease has raised hopes for new treatments to ease symptoms and slow functional decline. As such, there has been a push towards designing efficient pharmacological trials (i.e., drug trials), especially with regard to selecting outcomes measures that are both brief and sensitive to changes across the course of the disease, from subtle prodromal changes, to more severe end-stage changes. Objectives: Recently, to aid in efficient development of new HD research studies, the National Institute of Neurological Disorders and Stroke (NINDS) published recommendations for measurement selection in HD. While these recommendations are helpful, many of the recommended measures have little published data in HD. As such, we conducted a systematic review of the literature to identify the most common outcomes measures used in HD clinical trials. Methods: Major medical databases, including PubMed, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials, were used to identify peer-reviewed journal articles in English from 2001 through April 2013; 151 pharmacological trials were identified. Results: The majority of HD clinical trials employed clinician-reported outcomes measures (93%); patient reported outcome measures (11%) and observer reported outcome measures (3%) were used with much less frequency. Conclusions: We provide a review of the most commonly used measures across these trials, compare these measures to the clinical recommendations made by the NINDS working groups, and provide recommendations for selecting measures for future clinical trials that meet the Food and Drug Administration standards.
    Journal of Huntington's disease 10/2014; 3(3):233-52. DOI:10.3233/JHD-140115
Show more